Prediction Case File
YouTubeEvaluation Complete

Moderna MRNA Aktie: Ein Kauf in 2026? Langfristiges Setup?

1 extracted signal · 0 resolved · 0 still active

MCO Global Aktien profile imageMCO Global AktienIndependent analyst profile
Source published
17 Jul 2026, 11:10 UTC
Recorded by Tahlil Plus
17 Jul 2026, 11:13 UTC
Video preview for Moderna MRNA Aktie: Ein Kauf in 2026? Langfristiges Setup?
Source overview

AI-generated source summary

The analysis focuses on Moderna (MRNA), identifying a potential bullish trend. The current price is $62.89, with a target price of $100.00. The invalidation level, or fail bound, is set at $43.76. This suggests that if the price drops below $43.76, the bullish outlook would be compromised. The analysis is based on the 4-hour timeframe, indicating a medium-term outlook. The interpretation of the price action suggests that a correction is underway, potentially within an uptrend, with key support levels identified between $50.58 and $66.18. A bounce from this support zone is anticipated to continue the upward momentum towards the $100 target.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
1
Cancelled, invalid or excluded
Resolved success
—
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Source processing completed

    Source analysis and structured extraction completed.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  7. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

MCO Global Aktien

Platform-wide history, separate from this source evaluation.

Reliability
44.3
Tracked signals
111
Historical success
29.7%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail